drugset / Trial / NCT00769613
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
Phase 1
Unknown
20 enrolled
Milton S. Hershey Medical Center
National Cancer Institute (NCI) · collab
Open-labelSupportive care
Summary
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have undergone donor stem cell transplant and have cytomegalovirus infections.
Timeline
- Start
- 2008-08
- Primary completion
- 2014-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cytomegalovirus IE-1-specific cytotoxic T lymphocytes | Cell therapy | — | — |
| Subject | cytomegalovirus pp65-specific cytotoxic T lymphocytes | Cell therapy | — | — |
| Subject | therapeutic allogeneic lymphocytes | Cell therapy | — | — |